Skip to content
Back to ATTO

Attovia Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
55
Purchases
9
Sales
46
Purchase value
$42.08M
Sale value
$2.25M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Colin WalshDirector
4/AAmendment
Filed Aug 28, 2026Period of report Aug 5, 20260001866174-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseAug 6, 2026
Common StockF4F1F2500,000$17.00$8.50M3,020,632IndirectSee Footnotes
PurchaseAug 5, 2026
Common StockF1F2F385,000$21.00$1.79M85,000IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3988$22.03$21.77K84,012IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3447$21.87$9.78K83,565IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,332$22.03$29.34K82,233IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3200$22.05$4.41K82,033IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,556$22.06$34.33K80,477IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F33,402$22.02$74.91K77,075IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3200$22.10$4.42K76,875IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3480$21.55$10.34K76,395IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3100$22.11$2.21K76,295IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3753$21.97$16.54K75,542IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3672$22.02$14.80K74,870IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F36,970$22.03$153.55K67,900IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3400$22.02$8.81K67,500IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,180$21.84$25.77K66,320IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,040$22.05$22.93K65,280IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3300$20.84$6.25K64,980IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3443$21.78$9.65K64,537IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3200$22.05$4.41K64,337IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3700$22.07$15.45K63,637IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,163$22.19$25.81K62,474IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3100$21.99$2.20K62,374IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F36,763$21.61$146.15K55,611IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F376,418$21.04$1.61M0IndirectSee Footnotes
Filing footnotes · 8
  1. F1The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
  2. F2These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
  3. F3GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.
  4. F4The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4.
  5. F5Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 9.29-for-1 basis upon the closing of the Issuer's initial public offering (the "IPO") on August 6, 2026 without payment of consideration. The Preferred Stock has no expiration date.
  6. F6The Reporting Person is a managing director of GS&Co, a subsidiary of The Goldman Sachs Group Inc. ("GS Group"). GS Group is the direct owner of GS&Co and an indirect owner of Goldman Sachs Asset Management, L.P. ("GSAM LP"). GS&Co is the manager of Broad Street Principal Investments L.L.C. ("BSPI") which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock of the Issuer. GSAM LP is the investment manager of WSLS Offshore Investments, SLP ("WSLS Offshore") which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock of the Issuer,... (continued in footnote 7)
  7. F7(continued from footnote 6)... West Street Life Sciences I, L.P. ("WSLS I") which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock of the Issuer, WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore") which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock of the Issuer, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore") which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock of the Issuer,... (continued in footnote 8)
  8. F8(continued from footnote 7)... GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group.
Open on SEC EDGAR
Broad Street Principal Investments, L.L.C.Former 10% Owner
Goldman Sachs Asset Management, L.P.Former 10% Owner
Goldman Sachs & Co. LLCFormer 10% Owner
Goldman Sachs Group IncFormer 10% Owner
West Street Life Sciences I, L.P.Former 10% Owner
WSLS EMP Offshore Investments, L.P.Former 10% Owner
WSLS EMP Onshore Investments, L.P.Former 10% Owner
WSLS Offshore Investments, SLPFormer 10% Owner
4/AAmendment
Filed Aug 28, 2026Period of report Aug 5, 20260000886982-26-000522
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseAug 6, 2026
Common StockF4F1F2500,000$17.00$8.50M3,020,632IndirectSee Footnotes
PurchaseAug 5, 2026
Common StockF1F285,000$21.00$1.79M85,000IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3988$22.03$21.77K84,012IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3447$21.87$9.78K83,565IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,332$22.03$29.34K82,233IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3200$22.05$4.41K82,033IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,556$22.06$34.33K80,477IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F33,402$22.02$74.91K77,075IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3200$22.10$4.42K76,875IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3480$21.55$10.34K76,395IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3100$22.11$2.21K76,295IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3753$21.97$16.54K75,542IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3672$22.02$14.80K74,870IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F36,970$22.03$153.55K67,900IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3400$22.02$8.81K67,500IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,180$21.84$25.77K66,320IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,040$22.05$22.93K65,280IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3300$20.84$6.25K64,980IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3443$21.78$9.65K64,537IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3200$22.05$4.41K64,337IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3700$22.07$15.45K63,637IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F31,163$22.19$25.81K62,474IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F3100$21.99$2.20K62,374IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F36,763$21.61$146.15K55,611IndirectSee Footnotes
SaleAug 5, 2026
Common StockF1F2F376,418$21.04$1.61M0IndirectSee Footnotes
Filing footnotes · 7
  1. F1Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
  2. F2These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
  3. F3GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.
  4. F4The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4.
  5. F5All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO").
  6. F6This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7)
  7. F7(continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group.
Open on SEC EDGAR
venBio Global Strategic Fund IV, L.P.10% owner
4
Filed Aug 10, 2026Period of report Aug 6, 20260000905148-26-003548
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseAug 6, 2026
Common StockF2382,352$17.00$6.50M4,181,367Direct
Filing footnotes · 2
  1. F1In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration.
  2. F2These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV.
Open on SEC EDGAR
Sanofi10% owner
4
Filed Aug 7, 2026Period of report Aug 6, 20260001193125-26-340173
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseAug 6, 2026
Common StockF2F3300,000$17.00$5.10M1,082,855IndirectSee footnote
Filing footnotes · 3
  1. F1The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026.
  2. F2Represents a purchase in the Issuer's IPO.
  3. F3Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
Open on SEC EDGAR
Green Jeremy10% owner
Redmile Biopharma Investments III, L.P.10% owner
Redmile Group, LLC10% owner
4
Filed Aug 7, 2026Period of report Aug 6, 20260001104659-26-092867
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseAug 6, 2026
Common StockF2F4200,000$17.00$3.40M982,854Direct
PurchaseAug 6, 2026
Common StockF3F4400,000$17.00$6.80M1,182,854IndirectSee footnotes
Filing footnotes · 4
  1. F1On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering ("IPO"), for no consideration. The Series B Preferred Stock had no expiration date.
  2. F2These securities are held directly by Redmile Biopharma Investments III, L.P. ("RBI III"), which is managed by Redmile Group, LLC ("Redmile"). RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that RBI III is the beneficial owner of the reported securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
  3. F3These securities were purchased in the IPO by certain private investment vehicles managed by Redmile (collectively, the "Redmile Clients"), and include the number of securities purchased by RBI III in the IPO reported in the line above.
  4. F4Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open on SEC EDGAR
Fhmls XI, L.L.C.10% owner
Fhmls XI, L.P.10% owner
Frazier Life Sciences XI, L.P.10% owner
4
Filed Aug 6, 2026Period of report Aug 6, 20260001231919-26-000838
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseAug 6, 2026
Common StockF2588,235$17.00$10.00M6,154,213Direct
Filing footnotes · 5
  1. F1The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
  2. F2The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.
  3. F3The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
  4. F4The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
  5. F5The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.